drugset / Trial / NCT01524224
A Dose-Escalation Study in Participants With Advanced Cancer
SequentialOpen-labelTreatment
Summary
This study is a multicenter, open-label, dose-escalation phase 1 study of intravenous (IV) LY2495655 in participants with advanced cancer.
Timeline
- Start
- 2008-01
- Primary completion
- 2012-11
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LANDOGROZUMAB | Monoclonal antibody | 2 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 7 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 21 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 70 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 210 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 700 mg | Intravenous |
Indications
No indication recorded.